Close Menu

NEW YORK – After having fallen 3 percent in February, the GenomeWeb Index fell 3 percent again in March.

The index underperformed the Dow Jones Industrial Average and the Nasdaq, which rose 7 percent and rose a fraction of a percent, respectively, in March. However, the index outperformed the Nasdaq Biotechnology Index, which fell 4 percent last month. Individual stock performances in the GenomeWeb Index were largely negative last month, as 14 of the 37 stocks saw gains and 23 saw losses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.